Investors

Vaccine boosters could have a dual positive impact on the Covid-19 pandemic. They can boost the immune response against the original SARS-CoV-2 virus, as well as provide methods to overcome the emerging viral variants that could render existing vaccines ineffective....

AXIM Biotechnologies (OTCQB:AXIM) has completed point-of-care clinical trials on its ImmunoPass rapid test that semi-quantitatively measures levels of COVID-19 neutralizing antibodies. The test aims to help understand COVID-19 immunity, validate vaccine’s...

The CDC estimates that in the past 20 years, vaccines have saved more that 21 million lives. There are many different types of vaccines that provide protection against infectious diseases. Some examples of diseases for which vaccines elicit protective immunity include...

John Huemoeller, CEO of AXIM Biotechnologies, an international healthcare solutions company based in San Diego targeting oncological and COVID-19 research, discusses three first-of-their-kind COVID-19 neutralizing antibody tests. They have developed the world’s first...

AXIM Biotechnologies (OTCQB:AXIM) announces the start of clinical trials for ImmunoPass, the company’s rapid point-of-care test that semi-quantitatively measures levels of neutralizing antibodies to COVID-19. Measuring neutralizing antibodies in people after...